Myasthenia Gravis is an adult neuromuscular disorder that affects approximately 5 in 100,000 people.
It is due to a dysfunction of the immune system: the autoimmune reaction is directed against constituents of the neuromuscular junction, the interface between the nerve and the muscle, which results in a defect of transmission of the nerve impulse. This is manifested by fatigability and a lack of muscle strength.
Clinical trial ongoing at the Institute:
- RA101495-02.301 : A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Confirm the Efficacy, Safety, and Tolerability of Zilucoplan in Subjects with Generalized Myasthenia Gravis
Acronym |
RA101495-02.301 |
| Study type | RIPH1 |
| Intervention | Zilucoplan |
| Principal investigator | Anthony Behin |
| Sponsor | RAPharma |
| Fundings | RAPharma |
| Study status | In preparation |
| Recruitment status | In preparation |
| Population | Adult |
| + infos on clinicaltrials.gov |
